Brief: Monte Rosa Therapeutics Announces Initiation Of Ind Enabling Studies For Mrt-8102
11/03/2024 11:48
March 11 (Reuters) - Monte Rosa Therapeutics Inc
GLUE.O :
* MONTE ROSA THERAPEUTICS ANNOUNCES INITIATION OF IND
ENABLING
STUDIES FOR MRT-8102, A FIRST-IN-CLASS NEK7 DIRECTED MOLECULAR
GLUE DEGRADER AND NLRP3/IL-1Β PATHWAY INHIBITOR
* MONTE ROSA THERAPEUTICS INC: IND-ENABLING STUDIES ONGOING;
IND
SUBMISSION ANTICIPATED IN Q1 2025
Source text for Eikon: ID:nGNX45y1CF
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million